NeuroDerm Ltd. (NASDAQ:NDRM) – Equities researchers at Roth Capital reduced their FY2016 EPS estimates for NeuroDerm in a research note issued on Tuesday. Roth Capital analyst S. Henry now anticipates that the brokerage will earn ($1.41) per share for the year, down from their previous forecast of ($1.39). Roth Capital also issued estimates for NeuroDerm’s Q4 2016 earnings at ($0.43) EPS, FY2019 earnings at ($1.00) EPS and FY2020 earnings at $0.00 EPS.

Several other research analysts have also issued reports on NDRM. Zacks Investment Research lowered shares of NeuroDerm from a “hold” rating to a “sell” rating in a research report on Tuesday, August 30th. Jefferies Group increased their price target on shares of NeuroDerm from $28.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, September 6th.

NeuroDerm (NASDAQ:NDRM) traded up 0.51% on Thursday, reaching $19.80. The company’s stock had a trading volume of 10,241 shares. NeuroDerm has a 1-year low of $11.76 and a 1-year high of $20.52. The stock has a 50 day moving average price of $18.19 and a 200-day moving average price of $17.48. The company has a market capitalization of $430.06 billion, a price-to-earnings ratio of 15.00 and a beta of 1.04.

NeuroDerm (NASDAQ:NDRM) last released its quarterly earnings data on Thursday, August 25th. The company reported ($0.32) EPS for the quarter, meeting the consensus estimate of ($0.32).

Hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new stake in NeuroDerm during the second quarter valued at $246,000. ProShare Advisors LLC raised its stake in NeuroDerm by 1.1% in the second quarter. ProShare Advisors LLC now owns 16,119 shares of the company’s stock valued at $262,000 after buying an additional 173 shares during the last quarter. State Street Corp purchased a new stake in NeuroDerm during the second quarter valued at $320,000. Swiss National Bank raised its stake in NeuroDerm by 50.0% in the second quarter. Swiss National Bank now owns 22,800 shares of the company’s stock valued at $371,000 after buying an additional 7,600 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in NeuroDerm during the third quarter valued at $469,000. 42.93% of the stock is owned by institutional investors.

About NeuroDerm

NeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa/carbidopa (LD/CD) or apomorphine concentrations and dosages.

5 Day Chart for NASDAQ:NDRM

Receive News & Stock Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related stocks with our FREE daily email newsletter.